Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Developments in Health Economics and Public Policy
|
October 28, 1999
The market for pharmaceuticals
K Bergenheim, U Braun
Diabetes, Obesity & Metabolism
|
July 2, 2010
A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes
P McEwan, M Evans, K Bergenheim
Alimentary Pharmacology & Therapeutics
|
August 17, 2002
Patient-centred endpoints in economic evaluations of gastro-oesophageal reflux disease
N Vakil, T Rydén-Bergsten, K Bergenheim
Diabetes, Obesity & Metabolism
|
April 27, 2010
Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model
P McEwan, M Evans, H Kan, et al.
Pharmacoeconomics
|
October 27, 2014
Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK
P McEwan, H Bennett, T Ward, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Comparing the Use of Patient-Level Data to An Average Patient Profile Within a Type 2 Diabetes Simulation Model
P McEwan, H Bennett, T Ward, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Comparing the Event Prediction Capability of the Ukpds68 and Hong Kong Diabetes Risk Equations within A Type 2 Diabetes Simulation Model
P McEwan, T Ward, H Bennett, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
January 30, 2018
Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA<sub>1c</sub> , weight and hypoglycaemic event incidence
P McEwan, H Bennett, K Bolin, et al.
Current Medical Research and Opinion
|
December 25, 2015
Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea
G Lozano-Ortega, S Goring, H A Bennett, et al.
BMC Health Services Research
|
November 7, 2015
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
M Charokopou, P McEwan, S Lister, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Developments in Health Economics and Public Policy
|
October 28, 1999
The market for pharmaceuticals
K Bergenheim, U Braun
Diabetes, Obesity & Metabolism
|
July 2, 2010
A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes
P McEwan, M Evans, K Bergenheim
Alimentary Pharmacology & Therapeutics
|
August 17, 2002
Patient-centred endpoints in economic evaluations of gastro-oesophageal reflux disease
N Vakil, T Rydén-Bergsten, K Bergenheim
Diabetes, Obesity & Metabolism
|
April 27, 2010
Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model
P McEwan, M Evans, H Kan, et al.
Pharmacoeconomics
|
October 27, 2014
Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK
P McEwan, H Bennett, T Ward, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Comparing the Use of Patient-Level Data to An Average Patient Profile Within a Type 2 Diabetes Simulation Model
P McEwan, H Bennett, T Ward, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Comparing the Event Prediction Capability of the Ukpds68 and Hong Kong Diabetes Risk Equations within A Type 2 Diabetes Simulation Model
P McEwan, T Ward, H Bennett, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
January 30, 2018
Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA<sub>1c</sub> , weight and hypoglycaemic event incidence
P McEwan, H Bennett, K Bolin, et al.
Current Medical Research and Opinion
|
December 25, 2015
Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea
G Lozano-Ortega, S Goring, H A Bennett, et al.
BMC Health Services Research
|
November 7, 2015
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
M Charokopou, P McEwan, S Lister, et al.
Page
of 2